FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns the use of a non-immunosuppressive derivative of cyclosporine A for reducing mitochondrial dysfunction and a degree of apoptosis in patient's cells with diagnosed congenital Ullrich myopathy or Bethlem myopathy.
EFFECT: invention provides considerable reduction of a degree of apoptosis and mitochondrial dysfunction.
5 cl, 5 ex, 6 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MODIFIED CYCLOSPORINES | 2007 |
|
RU2463071C2 |
| APPLICATION OF MODIFIED CYCLOSPORINS FOR TREATING HCV INDUCED DISEASES | 2004 |
|
RU2389501C2 |
| CYCLOSPORINE | 1991 |
|
RU2085589C1 |
| MODIFIED CYCLOSPORIN THAT CAN BE USED AS PRODRUG AND ITS USING | 2002 |
|
RU2290196C2 |
| DERIVATIVES OF CYCLOSPORIN, METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION BASED ON SAID | 1993 |
|
RU2131883C1 |
| AGENT FOR HAIR GROWTH CONTAINING 3-SUBSTITUTED CYCLOSPORINE DERIVATIVE | 2002 |
|
RU2291682C2 |
| COMBINATION OF SIROSINGOPIN AND MITOCHONDRIAL INHIBITORS FOR TREATMENT OF CANCER AND FOR IMMUNOSUPPRESSION | 2012 |
|
RU2602937C2 |
| METHOD OF PREPARING CYCLOSPORIN | 1996 |
|
RU2170741C2 |
| CYCLOSPORIN ANALOGS MOLECULES MODIFIED BY 1 AND 3 AMINO ACIDS | 2011 |
|
RU2630690C9 |
| METHOD FOR REDUCTION OF OXIDISING INJURY (VERSIONS) | 2005 |
|
RU2376028C2 |
